Vascugen is a leading brand dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow to tissues. With a focus on diabetic patients at high risk for limb amputation and associated morbidity, Vascugen's mission is to develop advanced medicines for life-threatening conditions resulting from insufficient microvascular circulation. Fueled by a partnership with Indiana University (IU), a renowned institution for medical research, Vascugen launched in 2018 with the goal of restoring circulation in afflicted patients who lack treatment options.

Their lead program is an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell, capable of forging new blood vessels in oxygen-starved tissues. The company holds exclusive rights to a broad technology portfolio developed in the laboratory of their scientific founder, Mervin C. Yoder, MD.

By harnessing Nobel Prize-winning technologies, including induced pluripotent stem cells (iPSCs) and gene modification, Vascugen aims to advance an allogeneic, donor-independent cell replacement therapy for microvascular regeneration. Manufacturing-wise, Vascugen utilizes an integrated approach, mitigating technology and tech transfer risks. Their R&D facility houses a state-of-the-art cleanroom designed to industry standards, and they maintain dedicated quality assurance and management systems for compliance and product release